Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744341 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
A Phase 2 study, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00744341 is a Phase 2 study that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT00744341, a Phase 2 study, was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
Interventions
- DRUG Placebo
- DRUG SLV320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744341
The ClinicalTrials.gov registry entry for NCT00744341 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00744341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744341 about?
NCT00744341 is a clinical study titled "Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure". The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
What is the current status of trial NCT00744341?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2009-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00744341?
The interventions under investigation include: Placebo (DRUG), SLV320 (DRUG).
Who is sponsoring clinical trial NCT00744341?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.